CORRECTION article

Front. Immunol., 26 November 2024

Sec. Cancer Immunity and Immunotherapy

Volume 15 - 2024 | https://doi.org/10.3389/fimmu.2024.1527232

Corrigendum: Case report: A golden tail of immunotherapy: significant tail effect in a chemotherapy-resistant advanced pulmonary sarcomatoid carcinoma patient treated by Sintilimab combined with Anlotinib

  • CF

    Chenghao Fu 1,2

  • HD

    Haonan Du 1

  • QW

    Qiang Wang 3

  • WZ

    Weiyou Zhu 1

  • GB

    Guangli Bian 4

  • ZZ

    Zhujuan Zhong 5

  • YW

    Yuheng Wang 2

  • LC

    Lei Cao 6*

  • 1. Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China

  • 2. Department of Thoracic Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China

  • 3. Department of Thoracic Surgery, Taizhou Fourth People’s Hospital, Taizhou, Jiangsu, China

  • 4. Department of Radiology, The Affiliated Suqian First People’s Hospital of Nanjing Medical University, Suqian, Jiangsu, China

  • 5. Department of Pathology, The Affiliated Suqian First People’s Hospital of Nanjing Medical University, Suqian, Jiangsu, China

  • 6. Department of Oncology, The Affiliated Suqian First People’s Hospital of Nanjing Medical University, Suqian, Jiangsu, China

In the published article, there was an error in affiliations 4, 5, 6. Instead of “The First People’s Hospital of Suqian”, it should be “The Affiliated Suqian First People’s Hospital of Nanjing Medical University”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

tail effect, immunotherapy, cancer therapy, PSC, ICI, Sintilimab

Citation

Fu C, Du H, Wang Q, Zhu W, Bian G, Zhong Z, Wang Y and Cao L (2024) Corrigendum: Case report: A golden tail of immunotherapy: significant tail effect in a chemotherapy-resistant advanced pulmonary sarcomatoid carcinoma patient treated by Sintilimab combined with Anlotinib. Front. Immunol. 15:1527232. doi: 10.3389/fimmu.2024.1527232

Received

13 November 2024

Accepted

14 November 2024

Published

26 November 2024

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

15 - 2024

Updates

Copyright

*Correspondence: Lei Cao,

†These authors have contributed equally to this work

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics